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Abstract Thus far the clinical beneﬁts seen in breast
cancer patients treated with drugs targeting the vascular
endothelial growth factor (VEGF) pathway are only mod-
est. Consequently, additional antiangiogenic approaches for
treatment of breast cancer need to be investigated. Throm-
bospondin-2 (TSP-2) has been shown to inhibit tumor
growth and angiogenesis with a greater potency than the
related molecule TSP-1. The systemic effects of TSP-2 on
tumor metastasis and the underlying molecular mechanisms
of the antiangiogenic activity of TSP-2 have remained
poorly understood. We generated a recombinant fusion
protein consisting of the N-terminal region of TSP-2 and the
IgG-Fc1 fragment (N-TSP2-Fc) and could demonstrate that
the antiangiogenic activity of N-TSP2-Fc is dependent on
the CD36 receptor. We found that N-TSP2-Fc inhibited
VEGF-induced tube formation of human dermal micro-
vascular endothelial cells (HDMEC) on matrigel in vitro
and that concurrent incubation of anti-CD36 antibody with
N-TSP2-Fc resulted in tube formation that was comparable
to untreated control. N-TSP2-Fc potently induced apoptosis
of HDMEC in vitro in a CD36-dependent manner. More-
over, we could demonstrate a CD36 receptor-mediated loss
of mitochondrial membrane potential and activation of
caspase-3 in HDMEC in vitro. Daily intraperitoneal injec-
tions of N-TSP2-Fc resulted in a signiﬁcant inhibition of the
growth of human MDA-MB-435 and MDA-MB-231 tumor
cells grown in the mammary gland of immunodeﬁcient
nude mice and in reduced tumor vascularization. Finally,
increased serum concentrations of N-TSP2-Fc signiﬁcantly
inhibited regional metastasis to lymph nodes and distant
metastasis to lung as shown by quantitative real-time alu
PCR. These results identify N-TSP2-Fc as a potent systemic
inhibitor of tumor metastasis and provide strong evidence
for an important role of the CD36 receptor in mediating the
antiangiogenic activity of TSP-2.
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Introduction
There is large amount of evidence that tumor growth is
dependent on angiogenesis [8, 15, 16]. Clinically, proof of
concept has begun with the recent regulatory approvals of
three antiangiogenic therapies targeting the vascular
endothelial growth factor (VEGF) pathway. Despite early
beneﬁts seen in breast cancer patients treated with anti-
VEGF therapies [29], enduring efﬁcacy with regard to
survival beneﬁts is relatively modest [23]. In addition,
recent data provided strong evidence that tumors may
escape or become resistant to the antiangiogenic effects of
blocking the VEGF signaling pathway [14, 36]. Therefore,
additional antiangiogenic approaches need to be evaluated.
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DOI 10.1007/s10549-010-1085-7Two members of the thrombospondin (TSP) family [1, 22],
TSP-1 and TSP-2, are important naturally occurring angi-
ogenesis inhibitors. Both proteins were shown to have
potent antiangiogenic activity by inhibiting endothelial cell
proliferation, migration, and tube formation in response to
multiple angiogenic stimuli [27, 50], and by inhibiting
angiogenic responses in a number of in vivo models [1].
The antiangiogenic activity of TSP-1 was localized to the
properdin-like type I repeats, also called thrombospondin
structural homology repeats (TSR), in the N-terminal
domain of TSP-1 [20]. In contrast to TSP-1, the molecular
mechanism of the antiangiogenic activity of TSP-2 has not
been as well studied. Since it has been reported that TSP-2
is more effective in inhibiting tumor growth and angio-
genesis than TSP-1 [25][ 28][ 45], we generated a recom-
binant fusion protein consisting of the N-terminal region of
TSP-2 and an IgG-Fc1 fragment (N-TSP2-Fc). N-TSP2-Fc
contained the procollagen homology domain as well as
three type I repeats of TSP-2. Here, we report that
recombinant N-TSP2-Fc induced apoptosis of endothelial
cells by CD36 receptor-mediated loss of mitochondrial
membrane potential and activation of caspase-3. In contrast
to the majority of experimental antiangiogenic studies that
only focused on the effects on primary tumor growth, with
much less attention on metastasis, we provide strong evi-
dence that N-TSP2-Fc signiﬁcantly inhibited tumor growth
of xenotransplanted MDA-MB-435 and MDA-MB-231
breast cancer cells and both lymph node as well as lung
metastasis of MDA-MB-435 tumor cells grown as xeno-
transplants in the mammary gland of nude mice.
Materials and methods
Cell lines and culture
HumanMDA-MB-435andMDA-MB-231breastcancercells
were obtained from ATCC and maintained in DMEM med-
ium (Invitrogen) containing 10% FCS, 4.5 mg/ml glucose,
2m ML-glutamine, 100 units/ml penicillin G, and 100 lg/ml
streptomycin.Human293-EBNA(Epstein-Barrvirusnuclear
antigen) cells (Invitrogen) were maintained in DMEM/F12
medium (Invitrogen) containing 10% FCS, 15 mM HEPES,
1.0 lg/ml puromycin, 100 units/ml penicillin G, 100 lg/ml
streptomycin, and 0.25 lg/ml fungizone, amphotericin B
(Invitrogen). Human dermal microvascular endothelial cells
(HDMEC) from Promocell (Heidelberg, Germany) were
cultured in ECGM-MV medium (Promocell) containing fetal
calf serum (0.05 ml/ml), endothelial cell growth supplement
(0.004 ml/ml), recombinant human epidermal growth factor
(10 ng/ml), heparin (22.5 lg/ml), hydrocortisone (1 lg/ml),
and phenol red (0.62 ng/ml) supplemented with 50 U/ml
penicillin and 50 lg/ml streptomycin.
Cell transfection
The coding sequences of the N-terminal region of TSP-2
(aa 18-550 of human TSP-2) and the Fc region of human
IgG1 (hinge and CH00 and CH3 domains) were obtained by
PCR and cloned into the the NheI and BamHI sites of a
modiﬁed pCEP4 expression vector [24] that contains a
cytomegalovirus enhancer/promoter, the EBNA-1 gene,
and a puromycin selection cassette. Human 293-EBNA
cells were stably transfected with the expression vector
using the Fugene transfection reagent (Roche).
Puriﬁcation of recombinant N-TSP2-Fc
The secreted fusion protein was puriﬁed from serum-free
culture medium by using afﬁnity chromatography with
Protein G Sepharose (GE Healthcare Europe). The fusion
protein was eluted with 0.1 M glycine (pH 2.7), and each
fraction was neutralized with 1 M Tris–HCl (pH 9.0). After
dialysis the protein was stored at -80C. The protein
concentration was determined using the BCA protein assay
kit (Pierce).
Tube formation assay
Twenty-four-well plates were coated with 300 ll Matri-
gel (BD Pharmingen) and incubated for 1 h at 37C.
HDMEC (1 9 10
5 cells) in ECGM-MV containing VEGF
(20 ng/ml) were seeded into duplicate and observed at
12 h. The formation of tube-like structures was analyzed
using an Olympus IX51 microscope. Images were cap-
tured and computer-assisted analyses of tube length were
performed using the Photoshop CS3 software (Adobe
Systems).
Apoptosis assay
Primary HDMEC incubated in ECGM containing
VEGF165 (R&D Systems) at a concentration of 20 ng/ml
were incubated with 40 lg/ml of N-TSP2-Fc with or
without concurrent addition of 10 lg/ml of blocking
CD36 antibody (Abcam) for 72 h. Apoptosis was evalu-
ated by using a procedure similar to that described by
Nicoletti et al. [32]. Brieﬂy, a pellet containing 1 9 10
6
HDMEC was gently resuspended in 500 ml of hypotonic
ﬂuorochrome solution containing 0.1% Triton X-100
(Sigma), 0.1% sodium citrate, and 50 mg/ml propidium
iodide (Sigma). After overnight incubation the cell sus-
pensions were assayed by ﬂow cytometry analysis of
cellular DNA content on a FACSCalibur equipment
(Becton-Dickinson Immunocytometry Systems) using
CellQuest software (Becton-Dickinson Immunocytometry
Systems).
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Human dermal microvascular endothelial cells cultured in
ECGM containing VEGF165 (R&D Systems) at a concen-
tration of 20 ng/ml were incubated with 40 lg/ml of
N-TSP2-Fc with or without concurrent addition of 10 lg/ml
of blocking CD36 antibody (Abcam) for 72 h. The mito-
chondrial membrane potential was analyzed using the
JC-1 mitochondrial membrane potential detection kit
(Biotium).
Western blot analysis of caspase-3 activity
Human dermal microvascular endothelial cells were treated
with N-TSP2-Fc (ﬁnal concentration 40 lg/ml) with or
without concurrent addition of 10 lg/ml of blocking CD36
antibody (Abcam) for 72 h. Cell lysates from HDMEC
were separated on SDS/PAGE under reducing conditions
and transferred to nitrocellulose membranes (HybonD-
ECL, GE Healthcare Europe, Munich, Germany) and then
immunoblotted with a rabbit anti-human active caspase-3
polyclonal antibody (BD Pharmingen). The speciﬁcally
bound antibody was detected using the enhanced chemi-
luminescence kit (Millipore). The bands were analyzed
using the Kodak image system (Kodak).
Tumorigenesis and metastasis assay
2 9 10
6 MDA-MB-435 or 5 9 10
6 MDA-MB-231 breast
cancer cells were injected bilaterally into the second
mammary fat pads of athymic, female, 6-week-old NCR
nu/nu mice. The tumor volumes were calculated using the
following formula: Volume = 4/3 9 p 9 (1/2 9 smaller
diameter)
2 9 1/2 9 larger diameter. After euthanizing the
mice, tumors, axillary lymph nodes, and lungs were
removed from each mouse. The tissue was embedded in
OCT compound or was snap frozen in liquid nitrogen. All
animal studies were done according to the German ethical
guidelines and the German laws for protection of animals.
Inhibition ELISA
Mice were intraperitoneally injected with N-TSP2-Fc
(100 lg/100 ll PBS). Serum samples were obtained at
various times (0, 0.5, 1, 2, 6, 12, and 24 h) after injection.
The concentration of TSP-2 was determined using an
inhibition ELISA. 96-well plates (MaxiSorbTM, Nunc)
were coated overnight with N-TSP2-Fc at a concentration
of 1 lg/ml. The remaining reactive sites were blocked with
1% BSA. A polyclonal goat antibody directed against the
N-terminal region of human TSP-2 (R&D) was previously
mixed in 96-well plates either with standard solutions of
N-TSP2-Fc (ranging from 2 pg/ml to 20 lg/ml) or with
mouse serum to be tested that was diluted 1:50 and 1:500
with PBS. This mixture was added to the N-TSP2-Fc-
coated wells and incubated for 2 h at RT. The samples
were assayed using a chemiluminescent substrate (Super-
Signal ELISA Pico substrate). Luminescence was mea-
sured at 425 nm using a multi-detection microplate reader
(BioTek Instruments GmbH). Data were analyzed using the
SigmaPlot software (Systat Software), and the concentra-
tion of TSP-2 in each sample was calculated from the
standard curve.
Analysis of tumor angiogenesis
Cryostat sections (5 lm) were stained with a rat anti-
mouse CD31 monoclonal antibody (BD Pharmingen).
Representative sections obtained from ﬁve tumors were
analyzed using an Olympus IX51 microscope. Images were
captured and morphometric analyses were performed using
the IP LAB software (Scanalytics) as described [45]. Three
different ﬁelds in each section were examined at 109
magniﬁcation, and the number of vessels per mm
2, the
vessel size, and the relative area occupied by tumor blood
vessels within the tumors were determined.
Quantitative analysis of metastasis
The DNEasy Blood and Tissue Kit (Qiagen) was used for
isolation of genomic DNA. Primers (Eurogentec) speciﬁc
for the human alu sequences (sense: 50-CATGGTGAAAC
CCCGTCTCTA-30; and antisense: 50-GCCTCAGCCTCC
CGAGTAG-30) were used to amplify human alu repeats
present in genomic DNA that was extracted from mouse
tissue. The internal TaqMan probe for alu (50-[YY]-AT
TAGCCGGGCGTGGTGGC-[BHQ-1]-30) was 50-labeled
with the reporter ﬂuorescent dye Yakima Yellow (YY)
and carried the non-ﬂuorescent quencher dye Black Hole
Quencher-1 (BHQ-1). The 18S rRNA control kit (Euro-
gentec) was used as an internal reference and was labeled
with the reporter dye 6-carboxy-ﬂuorescein (FAM) at the
50 end and the quencher dye 6-carboxy-tetramethyl-rho-
damin (TAMRA) at the 30 end. PCRs were carried out in
25 ll using 29TaqMan Universal PCR Master Mix
(Applied Biosystems), 0.9 lM each alu speciﬁc oligonu-
cleotide primer, 250nM internal alu probe, 1.5 ll 18S
rRNA primer mix, 0.5 ll internal 18S rRNA probe, and
1 ll genomic DNA. The ﬁnal concentration for genomic
DNA was 5 ng/ll for lymph node tissue and 50 ng/ll for
lung tissue. PCR was carried out for 2 min at 50C and
for 10 min at 95C followed by 40 cycles of 15 s at 95C
and 1 min at 60C using the ABI PRISM
TM 7700
Sequence Detector (Applied Biosystems). Serial dilution
steps (1:10) of genomic DNA obtained from human
MDA-MB-435 cells in genomic DNA were obtained from
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struct the calibration curves. The cycle at which the alu
PCR product becomes detectable above background sig-
nal (Ctalu) was determined for each dilution series. The
alu signal was normalized against the relative quantity of
18S rRNA and expressed as DCt = Ctalu - Ct18SrRNA.A
standard curve was generated for each measurement by
using the real-time PCR assay and by plotting DCt as a
function of the relative amount of human DNA in murine
DNA (%). The R
2 value (correlation coefﬁcient) was
[0.96 for all measurements demonstrating an excellent
relationship between the alu signal and the relative
amount of human DNA with a detection limit of 0.001%
human DNA in murine DNA.
Statistical analysis
The two-sided unpaired t-test was used to analyze the
tumor and metastasis data and to analyze the differences in
microvessel density, vessel size, and total vascular area.
Tube formation, apoptosis, mitochondrial membrane
potential, and caspase-3 activity were analyzed for signif-
icant differences by one-way ANOVA followed by Stu-
dent–Newman–Keuls’ test for comparison of individual
groups, after a Bartlett test had shown that variances were
homogenous.
Results
N-TSP2-Fc inhibits tube formation of CD36 positive
endothelial cells
Puromycin-selected human 293-EBNA cell clones secret-
ing high amounts of N-TSP2-Fc were used for large-scale
expression. The molecular weight of the puriﬁed recom-
binant protein was determined as approximately 110 kDa
by SDS-PAGE followed by western blot (data not shown).
N-terminal amino acid sequence analysis conﬁrmed that
the recombinant protein included amino acid 18–550 of
human TSP-2 containing the heparin-binding-domain, the
procollagen-like domain, and the three type 1 (properdin-
like) repeats. The antiangiogenic efﬁcacy was analyzed by
investigating the effect of N-TSP2-Fc on VEGF-induced
tube formation of HDMEC cultured on matrigel. After
12 h, formation of networks with interconnection of tube-
like structures was detected in HDMEC culture (Fig. 1a).
In contrast, only sparse tube-like structures were detected
when HDMEC were treated with N-TSP2-Fc (Fig. 1c)
resulting in a signiﬁcant reduction of the average tube
length by more than 50% (Fig. 1e). After incubation of
HDMEC with blocking CD36 antibody addition of
N-TSP2-Fc resulted in tube formation that was comparable
to untreated control (Fig. 1d, e) demonstrating that
Fig. 1 N-TSP2-Fc inhibits
HDMEC tube formation on
Matrigel in a CD36-dependent
manner. HDMEC were seeded
on Matrigel in the presence of
VEGF. Cultures were treated
with either PBS (a), or IgG-Fc
(b), or N-TSP2-Fc (c). In
d HDMEC were incubated with
both N-TSP2-Fc and blocking
CD36 antibody (CD36 ab).
(Bar = 200 lm). Quantitative
image analysis of tube length
(e) revealed that treatment with
N-TSP2-Fc signiﬁcantly
reduced the average tube length
as compared to control-treated
HDMEC. After preincubation of
HDMEC with a blocking CD36
antibody (CD36 ab) the average
tube length was comparable in
N-TSP2-Fc- and control-treated
HDMEC. Treatment with IgG-
Fc did not have any signiﬁcant
effects on the average tube
length. Data are expressed as
mean ± SEM (n = 3).
*** P\0.001
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nounced inhibition of network formation by N-TSP2-Fc.
Treatment of HDMEC with IgG-Fc did not show any sig-
niﬁcant effect on VEGF-induced network formation pro-
viding evidence that the Fc fragment is not involved in the
antiangiogenic activity of N-TSP2-Fc (Fig. 1b, e).
N-TSP2-Fc induces activation of apoptosis
in microvascular endothelial cells
Flow cytometry of the sub-G1 apoptotic population showed
that treatment of HDMEC with N-TSP2-Fc for 72 h in the
presence of VEGF resulted in a signiﬁcant increase of
apoptotic endothelial cells by more than 45% as compared
to control-treated cells (Fig. 2a). Parallel incubation with
blocking CD36 antibody attenuated N-TSP2-Fc-induced
apoptosis in HDMEC to close to the basal level indicating
that CD36 is required for the apoptotic activity of N-TSP2-
Fc (Fig. 2a).
N-TSP2-Fc causes activation of caspase-3
and of the mitochondrial-dependent intrinsic pathway
of apoptosis
Treatment of HDMEC with N-TSP2-Fc for 72 h resulted in
a signiﬁcant loss of mitochondrial membrane potential and
decreased the mitochondrial membrane potential to 66% of
control (=100%; P\0.001). When HDMEC were treated
with CD36 blocking antibody, addition of N-TSP2-Fc
failed to induce loss of mitochondrial membrane potential
(Fig. 2b). In addition, treatment of HDMEC with N-TSP2-
Fc for 72 h signiﬁcantly induced activation of caspase-3 by
more than 100% as compared to PBS control (Fig. 2c, d).
The activation of caspase-3 by N-TSP2-Fc was almost
Fig. 2 N-TSP2-Fc induces apoptosis of HDMEC by CD36 receptor-
mediated loss of mitochondrial membrane potential and activation of
caspase-3. Percentage of apoptotic HDMEC (a) was measured by
ﬂow cytometry. Treatment with N-TSP2-Fc resulted in a signiﬁcant
increase of HDMEC apoptosis (a). Concurrent addition of a blocking
CD36 antibody (CD36 ab) with N-TSP2-Fc inhibited this effect (a).
The percentage of mitochondrial membrane potential (b) was
decreased after treatment of HDMEC with N-TSP2-Fc. Simultaneous
incubation of N-TSP2-Fc with anti-CD36 antibody (CD36 ab) did not
induce loss of mitochondrial membrane potential when compared to
control HDMEC (b). Active caspase-3 was analyzed in HDMEC by
western blot analysis (c). Image analysis (d) of the bands revealed that
caspase-3 activity was increased by incubation of HDMEC with
N-TSP2-Fc. Caspase-3 activity of control-treated HDMEC or HDMEC
incubated with N-TSP2-Fc and concurrent addition of anti-CD36
antibody (CD36 ab) was comparable (d). In all experiments a–d,
HDMEC were incubated with PBS (control), or with 40 lg/ml of N-
TSP2-Fc, or with 40 lg/ml of N-TSP2-Fc plus 10 lg/ml of blocking
CD36 antibody. All experiments were performed in the presence of
VEGF (20 ng/ml). Results are expressed as mean ? SEM (n = 3).
** P\0.01, *** P\0.001
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with blocking CD36 antibody (Fig. 2c, d).
Systemic treatment with N-TSP2-Fc inhibits tumor
growth and angiogenesis
MDA-MB-435 tumor cells were subcutaneously injected
into the second mammary gland of nude mice. Six days
after tumor cell injection mice received either vehicle
control (PBS), IgG-Fc (5 mg/kg/day), or N-TSP2-Fc
(5 mg/kg/day). Control-treated mice formed tumors reach-
ing a volume of *600 mm
3 within 21 days (Fig. 1S).
Following systemic treatment with N-TSP2-Fc for 15 days,
MDA-MB-435 tumors reached a volume of *220 mm
3,
representing a 63% inhibition of tumor growth (P\0.001;
Fig. 1S). At this time point, treatment with IgG-Fc did not
result in any major difference of tumor growth as compared
to control mice (P = 0.39; Fig. 1S). We next investigated
whether the prolongation of the growth period might change
the inhibitory effect on tumor growth by N-TSP2-Fc
(5 mg/kg body weight) treatment. After a growth period of
36 days the experiment had to be terminated due to tumor
burden and ﬁrst signs of tumor ulceration in the control
group according to the institutional regulations on animal
experiments. Systemic treatment was initiated 6 days after
tumor cell injection and continued daily for 30 days. The
inhibitory effect of N-TSP2-Fc became highly signiﬁcant at
day 22 of MDA-MB-435 tumor growth and was maintained
until the end of the growth period resulting in a 61% inhi-
bition of tumor growth at day 36, compared to control-
treated tumors (P\0.001; Fig 3a). To analyze tumor-
associated vascularization frozen sections of MDA-MB-
435 tumors were stained for the endothelial junction mol-
ecule CD31 [13]. Computer-assisted morphometric image
analysis revealed that both the vessel density (Fig. 3b) and
the average vessel size (Fig. 3c) was signiﬁcantly decreased
in N-TSP2-Fc-treated tumors, as compared with control
tumors, resulting in a signiﬁcant decrease in the relative
area occupied by tumor vessels by 67% (P\0.001;
Fig. 3d). To determine the serum concentration of both
TSP-2 and N-TSP2-Fc we established an inhibition ELISA
using an antibody directed against the N-terminal region of
TSP-2. The serum concentration of TSP-2 in untreated
tumor-bearing mice was 28.4 ± 3.6 ng/ml (Table 1).
Intraperitoneal administration of N-TSP2-Fc resulted in an
increase of the serum concentration of TSP-2 and this effect
lasted up to 24 h. Since intraperitoneal injection of PBS did
not result in any major differences in the serum concen-
tration of TSP-2 (data not shown) the observed higher level
of serum TSP-2 is due to an increase of the concentration of
recombinant N-TSP2-Fc. As early as 30 min after intra-
peritoneal injection we found a strong increase in the serum
level of N-TSP2-Fc (Table 1) that reached a peak at 1 h
after intraperitoneal injection. Afterward the serum
Fig. 3 Systemic treatment with N-TSP2-Fc inhibits in vivo growth
and angiogenesis of MDA-MB-435 tumors grown in the mammary
gland. PBS (control) or 5 mg per kg body weight of N-TSP2-Fc were
daily injected intraperitoneally, beginning at day 6 after tumor cell
implantation. MDA-MB-435 tumor growth was inhibited by treat-
ment with N-TSP2-Fc as compared with PBS control treatment (a).
Computer-assisted image analysis of CD31-stained cryostat tumor
sections revealed a signiﬁcant reduction of the number of blood
vessels per mm
2 tumor area (b), of the average vessel size (c), and of
the relative tumor area covered by blood vessels (d) in mice treated
with N-TSP2-Fc. CD31-stained blood vessels were evaluated in three
different 910 ﬁelds in sections obtained from ﬁve different tumors for
each treatment group. Data are expressed as mean ? SEM.
*** P\0.001
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injection and reached a serum concentration that was close
to the TSP-2 level of untreated tumor-bearing mice at 24 h
after intraperitoneal administration (Table 1). In addition,
we examined the effect of recombinant N-TSP2-Fc on in
vivo tumor growth of orthotopically injected MDA-MB-
231 breast cancer cells (Fig. 2S). One week after tumor cell
injection, mice were treated daily either with N-TSP2-Fc
(5 mg/kg body weight) or vehicle control. Four weeks after
tumor cell injection systemic treatment with N-TSP2-Fc
resulted in a signiﬁcant inhibition of xenotransplanted
MDA-MB-231 breast carcinomas as compared to control-
treated tumors (P\0.05; Fig. 2S).
Systemic treatment with N-TSP2-Fc decreases
metastasis
Results of alu PCR indicated the presence of human DNA
as early as 2 weeks after tumor cell injection in both lymph
node and lung tissue of tumor-bearing mice treated with
vehicle control (Fig. 4a, b). The relative amount of human
DNA in murine DNA at this time point was 0.41% in
lymph node tissue and 0.024% in lung tissue of tumor-
bearing mice as compared to the background signal of
7.4 9 10
-4 and 4.2 9 10
-3% in non-tumor-bearing mice,
respectively (Fig. 4a, b). Treatment of tumor-bearing mice
with N-TSP2-Fc resulted in a signiﬁcant reduction of both
lymph node and lung metastasis at 2 weeks after tumor
implantation (Fig. 4a, b). At 5 weeks after tumor cell
injection the relative amount of human tumor DNA was
reduced by 80% in lymph node tissue and by 68% in lung
tissue of N-TSP2-Fc-treated mice as compared to control
mice (Fig. 4a, b).
Discussion
TSP-2 is a potent endogenous inhibitor of tumor growth
and angiogenesis [17, 45]. The antitumoral effect of TSP-2
Table 1 Intraperitoneal injection of N-TSP2-Fc results in increased
serum level of TSP-2
Time (h) after
injection (i.p.)
Serum concentration
of TSP-2
0 0.0284 ± 0.0036 lg/ml
0.5 16.8 ± 1.8 lg/ml
1.0 19.7 ± 3.8 lg/ml
6.0 0.198 ± 0.053 lg/ml
12.0 0.179 ± 0.043 lg/ml
24.0 0.029 ± 0.0063 lg/ml
After intraperitoneal injection of 100 lg of N-TSP2-Fc diluted in
100 ll PBS, serum levels of TSP-2 were measured by an inhibition
ELISA using an antibody directed against the N-terminal region of
TSP2. Data revealed that serum concentration of TSP-2 rapidly
increased (0.5 h) and reached a peak at 1 h after intraperitoneal
injection. The serum concentration of TSP-2 was increased for 24 h
Fig. 4 N-TSP2-Fc inhibits lymph node and lung metastasis. Quan-
titative real-time PCR was used to analyze human alu repeats from
MDA-MB-435 tumor cells present in genomic murine DNA that was
extracted from lymph node (a) and lung tissue (b). Lymph node
(a) and lung (b) metastasis were analyzed at two and 5 weeks after
tumor cell implantation in mice treated either with PBS (control;
n = 10) or N-TSP2-Fc (NTF; n = 10). To measure the background
signal in murine lymph node and lung tissue, quantitative real-time
alu PCR was performed in non-tumor-bearing mice (mice w/o tumor).
Data revealed an increase of the percentage of human DNA in murine
DNA obtained from lymph node and lung tissue of tumor-bearing
mice at two and 5 weeks after tumor cell transplantation when
compared to mice without tumors indicating the metastatic spread of
MDA-MB-435 tumor cells to the lymph nodes and lung. Treatment
with N-TSP2-Fc resulted in a signiﬁcant reduction of the percentage
of human DNA in murine DNA obtained from lymph node and lung
tissue at two and 5 weeks after transplantation of MDA-MB-435
tumor cells in the mammary gland of nude mice. Values represent
mean ? SEM. * P\0.05, ** P\0.01, *** P\0.001
Breast Cancer Res Treat (2011) 128:337–346 343
123is stronger than the effect of TSP-1 [45]. However, the
exact molecular mechanism of the antiangiogenic activity
of TSP-2 has not been as well studied as that of TSP-1.
TSP-2 shows only low sequence homology to TSP-1 in the
procollagen region. Moreover, a recombinant fragment of
human TSP-2 that only included the N-terminal globular
domain and the procollagen homology domain failed to
signiﬁcantly inhibit tumor growth and angiogenesis [34].
Therefore, the antiangiogenic activity of TSP-2 might map
to the properdin-like type 1 repeats [46], which have been
implicated in the antiangiogenic activity of TSP-1 [12, 20,
49]. The antiangiogenic effects within the properdin-like
type 1 repeats of TSP-1 are mediated partly through
interaction of the CSVTCG sequence with the CD36
receptor on endothelial cells [11, 21, 46].
We produced a recombinant fusion protein, N-TSP2-Fc,
that encompasses the N-terminal globular region with all
three type 1 repeats containing two CSVTCG sequence
motifs within the ﬁrst and second type 1 repeats. N-TSP2-
Fc exerted potent antiangiogenic activity in vitro. We
found that N-TSP2-Fc signiﬁcantly inhibited HDMEC tube
formation and induced HDMEC apoptosis. N-TSP2-Fc also
resulted in a signiﬁcant increase of caspase-3 activity and a
signiﬁcant loss of mitochondrial membrane potential in
cultured HDMEC. Moreover, blockade of the CD36
receptor almost completely abrogated the reported in vitro
effects of N-TSP2-Fc, strongly suggesting that the antian-
giogenic activity of N-TSP2-Fc is mediated by CD36-
dependent induction of endothelial cell apoptosis and at
least in part through activation of the intrinsic apoptotic
pathway. This is in agreement with the previously reported
binding of TSP-2 to CD36 and lack of inhibition of angi-
ogenesis by TSP-2 in CD36 null mice [43]. The exact
molecular mechanisms through which TSP-2 and TSRs
induce activation of caspase-3 and promote CD36-medi-
ated apoptosis remain to be elucidated.
We investigated the efﬁcacy of systemic therapy with
N-TSP2-Fc on both tumor growth and metastasis. To this
end we made use of MDA-MB-435 tumor cells representing
a well-established orthotopic model system for the study of
breast cancer metastasis. MDA-MB-435 cells form primary
tumors when injected into the mammary fat pad of nude
mice, and spontaneously metastasize from these tumors to
the lymph nodes and lungs [37, 44, 52]. However, in a
microarray expression study MDA-MB-435 cells have
been reported to cluster with several melanoma cell lines
[39], and it has been speculated that that MDA-MB-435
cell is instead the M14 melanoma cell line, due to an early
cross-contamination of cell cultures [9, 38]. MDA-MB-435
cells have been shown to express melanocytic proteins [42]
as well as epithelial markers such as cytokeratin 19 and
secrete milk proteins and lipids [42] suggesting that MDA-
MB-435 breast cancer cells may have undergone a lineage
inﬁdelity during tumor progression [42]. Indeed, lineage
inﬁdelity has been seen in breast carcinomas that express
both epithelial and melanoma-associated proteins [33, 35].
Very recently, Chambers [9] reported that although cur-
rently available stocks of the MDA-MB-435 and M14 cell
lines were shown to be virtually identical at the karyotype
level [38], the conclusion that M14 and MDA-MB-435
cells are of M14 melanoma origin is inconsistent with the
fact that the M14 cell line derived from a male patient with
metastatic melanoma [10] and the female karyotypes of
both cell lines at present [9, 38]. Chambers [9] suggested
that the evidence from the literature rather is consistent
with cell lines being of MDA-MB-435 breast cancer origin
and that the MDA-MB-435 cell line represents a poorly
differentiated aggressive breast tumor line with expression
of both epithelial and melanocytic markers. In addition, in
a recent study on distinct gene mutation proﬁles among
luminal-type and basal-type breast cancer cell lines
Hollestelle et al. [19] revealed that the MDA-MB-435 cell
line was basal-type. They identiﬁed subtype-speciﬁc gene
mutation proﬁles revealing that basal-type breast cancers
may have a genetic basis similar to melanomas [18, 19].
Hollestelle et al. concluded conclusively that MDA-MB-
435 is a breast cancer cell line [18].
We provide strong evidence that intraperitoneally
injected N-TSP2-Fc sufﬁciently reached the blood circu-
lation as shown by an inhibition ELISA and thereby sys-
temically inhibited MDA-MB-435 tumor progression due
to an inhibition of angiogenesis. We could also demon-
strate that IgG-Fc did not have any major effects on MDA-
MB-435 tumor growth in vivo. In addition, the inhibitory
effect of recombinant N-TSP2-Fc on the growth of breast
carcinomas could be conﬁrmed by using of another, MDA-
MB-231 [7], breast cancer cell line. Systemic treatment
with N-TSP2-Fc also resulted in a signiﬁcant inhibition of
xenotransplanted MDA-MB-231 breast cancer cells. Our
ﬁndings are consistent with recently reported growth
inhibition of xenotransplanted A431 squamous cell carci-
nomas by intraperitoneal application of a recombinant
TSP-2 protein that include TSR sequences [34]. We have
combined the accuracy and sensitivity of real-time PCR
[30] with the human speciﬁcity of alu sequences [40, 48,
54] for direct quantitative evaluation of metastatic MDA-
MB-435 breast cancer cells in lymph nodes and lungs. As
early as 2 weeks after tumor cell injection we could detect
human tumor cell DNA in lymph node and lung tissue of
MDA-M-435 breast tumor-bearing mice. The amount of
human DNA in the lungs was much lower than that in the
lymph nodes, indicating that lymph node metastasis is an
earlier event than distant lung metastasis. This is consistent
with the clinical course of most breast cancer diseases [4,
31]. We also found signiﬁcantly less human tumor cell
DNA in the lymph nodes and lungs of N-TSP2-Fc-treated
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123mice as compared to control-treated mice. The inhibitory
effect on metastasis was maintained over the entire period
of in vivo tumor growth. Even at 5 weeks after tumor cell
inoculation, both lymph node and lung metastasis were
signiﬁcantly reduced in N-TSP2-Fc-treated mice.
Controversial ﬁndings have been reported regarding the
effectsofTSP-1onmetastasis[2,3][47][51].Recentinvitro
[2,5]and invivo [53]data suggestthat prometastatic effects
of endogenous TSP-1 may involve the activation of trans-
forming growth factor-b (TGF-b) via the unique sequence
KRFK found between the ﬁrst and second type 1 repeats of
TSP-1 [41]. Noteworthy, TSP-2 lacks the KRFK sequence,
andrecentstudieshavenotfoundanyevidenceforactivation
of latent TGF-b by TSP-2 [26]. Whether the lack of TGF-b
activationmayexplainthelackofanyreportedprometastatic
effectofTSP-2remainstobefurtherevaluated.Insupportof
this hypothesis are recentﬁndings demonstrating that lymph
node metastasis was only observed in TSP-2-null mice but
notinwild-typemice ina multistep chemicallyinduced skin
carcinogenesis protocol [17] whereas in a transgenic mouse
model of breast cancer pulmonary metastasis was increased
in TSP-1 null mice as compared to wild-type mice [53].
Recently, preclinical studies reported that angiogenesis
inhibitors targeting the VEGF signaling pathway reduced
primary tumor growth but promoted tumor invasiveness and
metastasis in vivo [14, 36]. Multi-targeting of parallel
angiogenesis regulating pathways have been proposed to
improve the beneﬁts of antiangiogenic drug therapy [6]. Our
results demonstrate that N-TSP2-Fc treatment potently
inhibits both tumor growth and metastasis in vivo mediated
by CD36-dependent inhibition of tumor angiogenesis, and
they indicate its potential use for antiangiogenic combina-
tion therapies to treat breast cancer.
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